{"id": "article-30139_0", "title": "Thyroid Cancer -- Continuing Education Activity", "content": "Thyroid cancer is a malignancy arising from the thyroid parenchymal cells. Its incidence is steadily increasing worldwide, while the mortality rate has remained stable over the past several years. The clinical behavior of thyroid cancer is highly variable, from indolent, slowly progressing tumors to highly aggressive tumors with high mortality rates. There are various new cutting-edge treatment options for advanced thyroid cancer, while there is also evidence against the overtreatment of low-risk thyroid cancers. Hence, a thorough understanding of the types of thyroid cancer and its management is of paramount importance in providing the appropriate treatment to the patient. This activity reviews the incidence, etiology, pathophysiology, diagnosis, and treatment of thyroid cancer and highlights the role of interprofessional communication in optimizing the care of these patients.", "contents": "Thyroid Cancer -- Continuing Education Activity. Thyroid cancer is a malignancy arising from the thyroid parenchymal cells. Its incidence is steadily increasing worldwide, while the mortality rate has remained stable over the past several years. The clinical behavior of thyroid cancer is highly variable, from indolent, slowly progressing tumors to highly aggressive tumors with high mortality rates. There are various new cutting-edge treatment options for advanced thyroid cancer, while there is also evidence against the overtreatment of low-risk thyroid cancers. Hence, a thorough understanding of the types of thyroid cancer and its management is of paramount importance in providing the appropriate treatment to the patient. This activity reviews the incidence, etiology, pathophysiology, diagnosis, and treatment of thyroid cancer and highlights the role of interprofessional communication in optimizing the care of these patients."}
{"id": "article-30139_1", "title": "Thyroid Cancer -- Continuing Education Activity", "content": "Objectives: Outline the epidemiology and risk factors of thyroid cancer. Describe the clinical presentation and detailed histopathology of the different types of thyroid cancer. Explain the different treatment options for patients with thyroid cancer. Highlight the importance of interprofessional teams in coordinating care to optimize outcomes for patients with thyroid cancer. Access free multiple choice questions on this topic.", "contents": "Thyroid Cancer -- Continuing Education Activity. Objectives: Outline the epidemiology and risk factors of thyroid cancer. Describe the clinical presentation and detailed histopathology of the different types of thyroid cancer. Explain the different treatment options for patients with thyroid cancer. Highlight the importance of interprofessional teams in coordinating care to optimize outcomes for patients with thyroid cancer. Access free multiple choice questions on this topic."}
{"id": "article-30139_2", "title": "Thyroid Cancer -- Introduction", "content": "Thyroid cancer is a malignancy of the thyroid parenchymal cells. The thyroid parenchyma consists of two major cell types, the thyroid follicular cells that give rise to differentiated thyroid cancer(DTC) and the parafollicular or C-cells that give rise to medullary thyroid carcinoma (MTC). DTC comprises papillary thyroid cancer(PTC), follicular thyroid cancer(FTC), and Hurthle cell cancer which account for 90-95% of all thyroid malignancies. MTC accounts for around 1\u00a0to 2%, and anaplastic thyroid carcinoma accounts for less than 1% of all thyroid cancers [1]", "contents": "Thyroid Cancer -- Introduction. Thyroid cancer is a malignancy of the thyroid parenchymal cells. The thyroid parenchyma consists of two major cell types, the thyroid follicular cells that give rise to differentiated thyroid cancer(DTC) and the parafollicular or C-cells that give rise to medullary thyroid carcinoma (MTC). DTC comprises papillary thyroid cancer(PTC), follicular thyroid cancer(FTC), and Hurthle cell cancer which account for 90-95% of all thyroid malignancies. MTC accounts for around 1\u00a0to 2%, and anaplastic thyroid carcinoma accounts for less than 1% of all thyroid cancers [1]"}
{"id": "article-30139_3", "title": "Thyroid Cancer -- Etiology", "content": "Familial occurrence of thyroid cancer is approximately 5% for PTC and FTC and 15\u00a0to 30% for MTC. [2] Over the last decades, the incidence of papillary thyroid cancer has increased worldwide, mostly due to early detection and advanced imaging technology with the risk of overdetection. [3] Mutations and translocations in the genes coding the mitogen-activated protein kinase (MAPK) cellular signaling pathway have been implicated in the genetic basis of most thyroid cancers. [4] Some of the common mutations are as follows:", "contents": "Thyroid Cancer -- Etiology. Familial occurrence of thyroid cancer is approximately 5% for PTC and FTC and 15\u00a0to 30% for MTC. [2] Over the last decades, the incidence of papillary thyroid cancer has increased worldwide, mostly due to early detection and advanced imaging technology with the risk of overdetection. [3] Mutations and translocations in the genes coding the mitogen-activated protein kinase (MAPK) cellular signaling pathway have been implicated in the genetic basis of most thyroid cancers. [4] Some of the common mutations are as follows:"}
{"id": "article-30139_4", "title": "Thyroid Cancer -- Etiology", "content": "PTC - Point mutation in the BRAF gene leading to BRAF V600E mutant kinase is the most common mutation leading to PTC (29\u00a0to 69%) and PTC-associated anaplastic thyroid cancer (0\u00a0to 12%). [5] Translocation of the RET-papillary thyroid cancer(RET/PTC) occurs in about 7% of PTC. [6] Mutations in RAS proto-oncogene occur in 10-20% of\u00a0follicular variant PTC (FVPTC). [2]", "contents": "Thyroid Cancer -- Etiology. PTC - Point mutation in the BRAF gene leading to BRAF V600E mutant kinase is the most common mutation leading to PTC (29\u00a0to 69%) and PTC-associated anaplastic thyroid cancer (0\u00a0to 12%). [5] Translocation of the RET-papillary thyroid cancer(RET/PTC) occurs in about 7% of PTC. [6] Mutations in RAS proto-oncogene occur in 10-20% of\u00a0follicular variant PTC (FVPTC). [2]"}
{"id": "article-30139_5", "title": "Thyroid Cancer -- Etiology", "content": "FTC - Mutations in RAS proto-oncogene are most common in\u00a0FTC (40\u00a0to 50%).\u00a0Translocation in PAX8\u2013peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) has been identified in around\u00a030\u00a0to 35% of FTC. [7]", "contents": "Thyroid Cancer -- Etiology. FTC - Mutations in RAS proto-oncogene are most common in\u00a0FTC (40\u00a0to 50%).\u00a0Translocation in PAX8\u2013peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) has been identified in around\u00a030\u00a0to 35% of FTC. [7]"}
{"id": "article-30139_6", "title": "Thyroid Cancer -- Etiology", "content": "Anaplastic - Inactivating mutation of the p53 tumor suppressor gene has been identified in addition to early inactivating mutations in about 50\u00a0to 80% of the cases with anaplastic thyroid cancer. [8] [9] [10] Also, 66% of anaplastic thyroid cancers have been identified to harbor mutations in the CTNNB1 gene. [5] RAS mutations are also associated with 20\u00a0to 40% of anaplastic thyroid cancers. MTC - Germline mutations of RET proto-oncogene in inherited forms of MTC (approximately 25% of MTC)\u00a0and RAS mutations in 25% of MTC. [11]", "contents": "Thyroid Cancer -- Etiology. Anaplastic - Inactivating mutation of the p53 tumor suppressor gene has been identified in addition to early inactivating mutations in about 50\u00a0to 80% of the cases with anaplastic thyroid cancer. [8] [9] [10] Also, 66% of anaplastic thyroid cancers have been identified to harbor mutations in the CTNNB1 gene. [5] RAS mutations are also associated with 20\u00a0to 40% of anaplastic thyroid cancers. MTC - Germline mutations of RET proto-oncogene in inherited forms of MTC (approximately 25% of MTC)\u00a0and RAS mutations in 25% of MTC. [11]"}
{"id": "article-30139_7", "title": "Thyroid Cancer -- Etiology", "content": "Several other uncommon gene mutations have been associated with the development of thyroid cancer, such as TERT mutations, especially highly aggressive PTC. [12] DTC can be inherited by autosomal dominant inheritance or appear as a part of tumor-susceptibility syndromes. [13]", "contents": "Thyroid Cancer -- Etiology. Several other uncommon gene mutations have been associated with the development of thyroid cancer, such as TERT mutations, especially highly aggressive PTC. [12] DTC can be inherited by autosomal dominant inheritance or appear as a part of tumor-susceptibility syndromes. [13]"}
{"id": "article-30139_8", "title": "Thyroid Cancer -- Etiology", "content": "Risk factors: Female sex, a family history of thyroid cancer, and radiation exposure of the thyroid gland during childhood\u00a0are the major risk factors associated with DTC. [14] [15] [16] [15] [14] A recent study showed that thyroid cancer affects both genders equally, as seen in autopsy reports, but it might be detected in women more frequently than men. The difference could be explained by access to medical care. [17]", "contents": "Thyroid Cancer -- Etiology. Risk factors: Female sex, a family history of thyroid cancer, and radiation exposure of the thyroid gland during childhood\u00a0are the major risk factors associated with DTC. [14] [15] [16] [15] [14] A recent study showed that thyroid cancer affects both genders equally, as seen in autopsy reports, but it might be detected in women more frequently than men. The difference could be explained by access to medical care. [17]"}
{"id": "article-30139_9", "title": "Thyroid Cancer -- Epidemiology", "content": "Thyroid cancer represents 1% to 4% of all malignancies and is the fifth most common cancer in women in the United States. [14] It has a female preponderance of around 3:1. [18] There has been a steady rise in the incidence of thyroid cancer globally; particularly, PTC detection has risen by 240% in the last three decades. [19] This increase in the incidence has been observed in both genders and among all\u00a0races\u00a0and is thought to be primarily due to an increasing trend in the rate of diagnostic imaging. [20] [21]", "contents": "Thyroid Cancer -- Epidemiology. Thyroid cancer represents 1% to 4% of all malignancies and is the fifth most common cancer in women in the United States. [14] It has a female preponderance of around 3:1. [18] There has been a steady rise in the incidence of thyroid cancer globally; particularly, PTC detection has risen by 240% in the last three decades. [19] This increase in the incidence has been observed in both genders and among all\u00a0races\u00a0and is thought to be primarily due to an increasing trend in the rate of diagnostic imaging. [20] [21]"}
{"id": "article-30139_10", "title": "Thyroid Cancer -- Epidemiology", "content": "PTC is the most common endocrine\u00a0cancer, responsible for 96% of all new and 66.8% of deaths due to endocrine cancers. [22] As was mentioned earlier, most thyroid cancers derive from the follicular epithelium, with PTC and FTC being far more common than anaplastic thyroid cancer. [23] [24]", "contents": "Thyroid Cancer -- Epidemiology. PTC is the most common endocrine\u00a0cancer, responsible for 96% of all new and 66.8% of deaths due to endocrine cancers. [22] As was mentioned earlier, most thyroid cancers derive from the follicular epithelium, with PTC and FTC being far more common than anaplastic thyroid cancer. [23] [24]"}
{"id": "article-30139_11", "title": "Thyroid Cancer -- Histopathology", "content": "PTC:\u00a0Microscopically, the unique characteristic feature of PTC is papillae formation. A papilla consists of layers of tumor cells surrounding a fibrovascular core. Follicles are typically absent in classic PTC. Typical cellular histomorphology includes cells with large and clear nuclei with finely granular chromatin, often described as ground-glass or \"Orphan Annie-eyed\" nuclei with nuclear grooving and intranuclear inclusion bodies. Psammoma bodies, which are calcified clumps of cells likely derived from necrosed papillae, are also common. [25]", "contents": "Thyroid Cancer -- Histopathology. PTC:\u00a0Microscopically, the unique characteristic feature of PTC is papillae formation. A papilla consists of layers of tumor cells surrounding a fibrovascular core. Follicles are typically absent in classic PTC. Typical cellular histomorphology includes cells with large and clear nuclei with finely granular chromatin, often described as ground-glass or \"Orphan Annie-eyed\" nuclei with nuclear grooving and intranuclear inclusion bodies. Psammoma bodies, which are calcified clumps of cells likely derived from necrosed papillae, are also common. [25]"}
{"id": "article-30139_12", "title": "Thyroid Cancer -- Histopathology", "content": "Some variants of PTC do not form papillae and are termed follicular variants of PTC, provided they still have the nuclear features of PTC. Variants of PTC such as tall cell variant, columnar variant, insular carcinoma, and diffuse sclerosing variant are more aggressive than classic PTC and are termed thyroid cancers with intermediate differentiation. [26]", "contents": "Thyroid Cancer -- Histopathology. Some variants of PTC do not form papillae and are termed follicular variants of PTC, provided they still have the nuclear features of PTC. Variants of PTC such as tall cell variant, columnar variant, insular carcinoma, and diffuse sclerosing variant are more aggressive than classic PTC and are termed thyroid cancers with intermediate differentiation. [26]"}
{"id": "article-30139_13", "title": "Thyroid Cancer -- Histopathology", "content": "FTC: The histological features of FTC can be highly variable, from\u00a0a well-differentiated follicular pattern to a poorly differentiated pattern with marked nuclear atypia, absence of follicles, extensive capsular or vascular invasion, and solid growth. The latter changes are associated with a poor prognosis. [27] As described above, features that are characteristic of PTC should be absent.\u00a0Differentiating a follicular carcinoma from a benign follicular adenoma can only be made based on extracapsular and/or vascular invasion. FTC is further classified as minimally invasive, encapsulated, angioinvasive, and widely invasive, depending on the extent of invasion. Hurthle cell carcinoma: This is characterized by the occurrence of eosinophilic oxyphilic cells with abundant cytoplasm (oncocytes) and prominent nucleoli. [28]", "contents": "Thyroid Cancer -- Histopathology. FTC: The histological features of FTC can be highly variable, from\u00a0a well-differentiated follicular pattern to a poorly differentiated pattern with marked nuclear atypia, absence of follicles, extensive capsular or vascular invasion, and solid growth. The latter changes are associated with a poor prognosis. [27] As described above, features that are characteristic of PTC should be absent.\u00a0Differentiating a follicular carcinoma from a benign follicular adenoma can only be made based on extracapsular and/or vascular invasion. FTC is further classified as minimally invasive, encapsulated, angioinvasive, and widely invasive, depending on the extent of invasion. Hurthle cell carcinoma: This is characterized by the occurrence of eosinophilic oxyphilic cells with abundant cytoplasm (oncocytes) and prominent nucleoli. [28]"}
{"id": "article-30139_14", "title": "Thyroid Cancer -- Histopathology", "content": "MTC:\u00a0Given its origin from the parafollicular C cells, its histological features are the presence of spindle-shaped cells with no follicle formation. Amyloid deposition and calcitonin immunoreactivity are typically present.", "contents": "Thyroid Cancer -- Histopathology. MTC:\u00a0Given its origin from the parafollicular C cells, its histological features are the presence of spindle-shaped cells with no follicle formation. Amyloid deposition and calcitonin immunoreactivity are typically present."}
{"id": "article-30139_15", "title": "Thyroid Cancer -- Histopathology", "content": "Anaplastic thyroid carcinoma: The usual histologic variants are spindle-cell, pleomorphic giant cell, and squamoid variants. [29] Most of these cancers can\u00a0consist of a\u00a0mixed morphology of 2 or 3 variants. Atypical mitosis and numerous mitotic figures are very common. These cancers are less likely to stain for thyroid transcription factor 1 (TTF1), PAX 8, or thyroglobulin.", "contents": "Thyroid Cancer -- Histopathology. Anaplastic thyroid carcinoma: The usual histologic variants are spindle-cell, pleomorphic giant cell, and squamoid variants. [29] Most of these cancers can\u00a0consist of a\u00a0mixed morphology of 2 or 3 variants. Atypical mitosis and numerous mitotic figures are very common. These cancers are less likely to stain for thyroid transcription factor 1 (TTF1), PAX 8, or thyroglobulin."}
{"id": "article-30139_16", "title": "Thyroid Cancer -- History and Physical", "content": "The most common presenting feature\u00a0in DTC is either neck swelling (detected by the patient or a clinician) or incidentally detected thyroid nodules on neck imaging. The risk of malignancy of a thyroid nodule in the general population is around 5\u00a0to 10%, with the risk being higher in men and extremes of age. [30]", "contents": "Thyroid Cancer -- History and Physical. The most common presenting feature\u00a0in DTC is either neck swelling (detected by the patient or a clinician) or incidentally detected thyroid nodules on neck imaging. The risk of malignancy of a thyroid nodule in the general population is around 5\u00a0to 10%, with the risk being higher in men and extremes of age. [30]"}
{"id": "article-30139_17", "title": "Thyroid Cancer -- History and Physical", "content": "A careful history and physical examination will help to differentiate low-risk vs. high-risk nodules, although these signs and symptoms lack specificity. Aspects in the patient's history that could be concerning for malignancy\u00a0include a sudden increase in the size of the nodule with pressure symptoms such as hoarseness of voice, dysphagia, dyspnea, or Horner's Syndrome, as well as a family history of thyroid cancer, childhood irradiation to the head and neck region, or the occurrence of systemic effects such as weight loss and fatigue. On physical examination of the neck, firmness of the nodule, immobility, and the presence of neck lymph nodes should trigger suspicion for malignancy and lead to further evaluation.", "contents": "Thyroid Cancer -- History and Physical. A careful history and physical examination will help to differentiate low-risk vs. high-risk nodules, although these signs and symptoms lack specificity. Aspects in the patient's history that could be concerning for malignancy\u00a0include a sudden increase in the size of the nodule with pressure symptoms such as hoarseness of voice, dysphagia, dyspnea, or Horner's Syndrome, as well as a family history of thyroid cancer, childhood irradiation to the head and neck region, or the occurrence of systemic effects such as weight loss and fatigue. On physical examination of the neck, firmness of the nodule, immobility, and the presence of neck lymph nodes should trigger suspicion for malignancy and lead to further evaluation."}
{"id": "article-30139_18", "title": "Thyroid Cancer -- History and Physical", "content": "On the other hand, anaplastic thyroid cancer can present as a rapidly enlarging neck mass and rapid occurrence of compressive symptoms of the aerodigestive tract. Some patients can present with constitutional symptoms such as fever, weight loss, and anorexia. [31] [32]", "contents": "Thyroid Cancer -- History and Physical. On the other hand, anaplastic thyroid cancer can present as a rapidly enlarging neck mass and rapid occurrence of compressive symptoms of the aerodigestive tract. Some patients can present with constitutional symptoms such as fever, weight loss, and anorexia. [31] [32]"}
{"id": "article-30139_19", "title": "Thyroid Cancer -- Evaluation", "content": "A thyroid function panel is the most appropriate initial evaluation in a patient with a thyroid nodule. A hyperthyroid state often correlates with a lower risk of malignancy; in such patients, a radionuclide uptake scan is indicated. If the nodule/nodules are identified as hyperfunctioning, fine-needle aspiration biopsy (FNAB) should generally be avoided. This is because these nodules are rarely malignant, and the FNAB results for hyperfunctioning nodules are often inaccurate. [30]", "contents": "Thyroid Cancer -- Evaluation. A thyroid function panel is the most appropriate initial evaluation in a patient with a thyroid nodule. A hyperthyroid state often correlates with a lower risk of malignancy; in such patients, a radionuclide uptake scan is indicated. If the nodule/nodules are identified as hyperfunctioning, fine-needle aspiration biopsy (FNAB) should generally be avoided. This is because these nodules are rarely malignant, and the FNAB results for hyperfunctioning nodules are often inaccurate. [30]"}
{"id": "article-30139_20", "title": "Thyroid Cancer -- Evaluation", "content": "Evaluation of the thyroid nodule when biochemically euthyroid or hypothyroid should begin with a high-resolution diagnostic thyroid ultrasound. This can help assess the nodules for high-risk features, detect additional nodules not felt on physical examination, evaluate for neck lymph nodes, and guide FNAB if warranted. High-risk\u00a0features on ultrasound include a significant increase in size from prior imaging, hypoechogenicity, irregular margins, size taller than wide, microcalcifications, a solid internal structure, extra-thyroidal extension, and central vascularity. The features associated with a lower risk of malignancy are a\u00a0purely cystic nodule, spongiform appearance, comet tail shadowing, and peripheral vascularity. The decision to subject a nodule for FNAB should be based on these radiological criteria with guidance from Thyroid Imaging Reporting and Data System (TIRADS)\u00a0or American Thyroid Association (ATA)\u00a0criteria, but importance should be given to clinical indications irrespective of imaging criteria. [33] [34] [35]", "contents": "Thyroid Cancer -- Evaluation. Evaluation of the thyroid nodule when biochemically euthyroid or hypothyroid should begin with a high-resolution diagnostic thyroid ultrasound. This can help assess the nodules for high-risk features, detect additional nodules not felt on physical examination, evaluate for neck lymph nodes, and guide FNAB if warranted. High-risk\u00a0features on ultrasound include a significant increase in size from prior imaging, hypoechogenicity, irregular margins, size taller than wide, microcalcifications, a solid internal structure, extra-thyroidal extension, and central vascularity. The features associated with a lower risk of malignancy are a\u00a0purely cystic nodule, spongiform appearance, comet tail shadowing, and peripheral vascularity. The decision to subject a nodule for FNAB should be based on these radiological criteria with guidance from Thyroid Imaging Reporting and Data System (TIRADS)\u00a0or American Thyroid Association (ATA)\u00a0criteria, but importance should be given to clinical indications irrespective of imaging criteria. [33] [34] [35]"}
{"id": "article-30139_21", "title": "Thyroid Cancer -- Evaluation -- Limitations of FNAB", "content": "Of note, the diagnostic accuracy of FNAB depends on the skill of the person performing the procedure as well as the pathologist interpreting the results, and it ranges between 70\u00a0to 97%. Approximately 17\u00a0to 20% of FNAB are classified as insufficient samples. [36] Also, since FNAB allows for the analysis of individual cellular features and not the overall architecture of the nodule, it is excellent for diagnosing PTC, but it cannot detect capsular or vascular invasions by FTC. As a result, while FNA can categorize certain findings as suspicious for FTC, a diagnosis of FTC can only be made\u00a0from the final pathology after surgical resection. [37] The same applies to Hurthle cell neoplasms.", "contents": "Thyroid Cancer -- Evaluation -- Limitations of FNAB. Of note, the diagnostic accuracy of FNAB depends on the skill of the person performing the procedure as well as the pathologist interpreting the results, and it ranges between 70\u00a0to 97%. Approximately 17\u00a0to 20% of FNAB are classified as insufficient samples. [36] Also, since FNAB allows for the analysis of individual cellular features and not the overall architecture of the nodule, it is excellent for diagnosing PTC, but it cannot detect capsular or vascular invasions by FTC. As a result, while FNA can categorize certain findings as suspicious for FTC, a diagnosis of FTC can only be made\u00a0from the final pathology after surgical resection. [37] The same applies to Hurthle cell neoplasms."}
{"id": "article-30139_22", "title": "Thyroid Cancer -- Evaluation -- Bethesda System for Reporting Thyroid Cytopathology", "content": "The FNAB result is usually reported by the Bethesda Criteria for Reporting Thyroid Cytology, which stratifies the biopsy results based on the cytology, and recommends a further course of action. [38] Bethesda Category 1 is indicative of non-diagnostic FNAB; re-aspiration is indicated. Bethesda Category 2 is suggestive of a benign nodule that can be followed clinically with periodic thyroid ultrasound as warranted.", "contents": "Thyroid Cancer -- Evaluation -- Bethesda System for Reporting Thyroid Cytopathology. The FNAB result is usually reported by the Bethesda Criteria for Reporting Thyroid Cytology, which stratifies the biopsy results based on the cytology, and recommends a further course of action. [38] Bethesda Category 1 is indicative of non-diagnostic FNAB; re-aspiration is indicated. Bethesda Category 2 is suggestive of a benign nodule that can be followed clinically with periodic thyroid ultrasound as warranted."}
{"id": "article-30139_23", "title": "Thyroid Cancer -- Evaluation -- Bethesda System for Reporting Thyroid Cytopathology", "content": "Bethesda Categories 3 (Atypia of undetermined significance, AUS or Follicular lesion of undetermined significance, FLUS) and 4 (follicular neoplasm, FN or suspicious for follicular neoplasm) suggests that the inclusion or exclusion of thyroid cancer is not clear, and these patients may benefit from repeat FNAB (Category 3), molecular testing, or lobectomy (Categories 3 and 4). Bethesda\u00a0Categories 5 (Suspicious for malignancy) and 6 (Malignant) usually require\u00a0surgery.", "contents": "Thyroid Cancer -- Evaluation -- Bethesda System for Reporting Thyroid Cytopathology. Bethesda Categories 3 (Atypia of undetermined significance, AUS or Follicular lesion of undetermined significance, FLUS) and 4 (follicular neoplasm, FN or suspicious for follicular neoplasm) suggests that the inclusion or exclusion of thyroid cancer is not clear, and these patients may benefit from repeat FNAB (Category 3), molecular testing, or lobectomy (Categories 3 and 4). Bethesda\u00a0Categories 5 (Suspicious for malignancy) and 6 (Malignant) usually require\u00a0surgery."}
{"id": "article-30139_24", "title": "Thyroid Cancer -- Evaluation -- Role of Molecular Testing in Thyroid Cancer", "content": "Molecular testing is generally used in Bethesda categories 3 and 4, where cytology is indeterminate. [34] Recently, testing for single mutations such as BRAF V600E or RET/PTC translocations was performed. While these tests yield good specificity (100%), their sensitivity is usually poor (50\u00a0to 60%). [39] [40] Molecular Diagnostic Approaches [41]", "contents": "Thyroid Cancer -- Evaluation -- Role of Molecular Testing in Thyroid Cancer. Molecular testing is generally used in Bethesda categories 3 and 4, where cytology is indeterminate. [34] Recently, testing for single mutations such as BRAF V600E or RET/PTC translocations was performed. While these tests yield good specificity (100%), their sensitivity is usually poor (50\u00a0to 60%). [39] [40] Molecular Diagnostic Approaches [41]"}
{"id": "article-30139_25", "title": "Thyroid Cancer -- Evaluation -- Role of Molecular Testing in Thyroid Cancer", "content": "Gene mutation profiling panel- such as the 7-gene panel that detects multiple genes including\u00a0BRAF\u00a0V600E,\u00a0HRAS\u00a0codon 61,\u00a0KRAS\u00a0codons 12/13, and\u00a0NRAS\u00a0codon 61 point mutations, and\u00a0RET/PTC1,\u00a0PAX8/PPAR\u03b3, and\u00a0RET/PTC3 translocations\u00a0which account for approximately 70% of thyroid cancer. [41] This panel has improved the sensitivity and the negative predictive of these tests to >90%. [42] Therefore, mutation tests are good rule-in tests for thyroid cancer. [43] A 167-Gene expression\u00a0classifier\u00a0provides a strong negative predictive value, while\u00a0its\u00a0positive predictive value is only around 50%. [41] Hence, gene expression classifier testing is a good rule-out test for thyroid cancer. However, recently a large multi-gene panel of mutation markers has been introduced, further improving sensitivity and specificity. [43] [44]", "contents": "Thyroid Cancer -- Evaluation -- Role of Molecular Testing in Thyroid Cancer. Gene mutation profiling panel- such as the 7-gene panel that detects multiple genes including\u00a0BRAF\u00a0V600E,\u00a0HRAS\u00a0codon 61,\u00a0KRAS\u00a0codons 12/13, and\u00a0NRAS\u00a0codon 61 point mutations, and\u00a0RET/PTC1,\u00a0PAX8/PPAR\u03b3, and\u00a0RET/PTC3 translocations\u00a0which account for approximately 70% of thyroid cancer. [41] This panel has improved the sensitivity and the negative predictive of these tests to >90%. [42] Therefore, mutation tests are good rule-in tests for thyroid cancer. [43] A 167-Gene expression\u00a0classifier\u00a0provides a strong negative predictive value, while\u00a0its\u00a0positive predictive value is only around 50%. [41] Hence, gene expression classifier testing is a good rule-out test for thyroid cancer. However, recently a large multi-gene panel of mutation markers has been introduced, further improving sensitivity and specificity. [43] [44]"}
{"id": "article-30139_26", "title": "Thyroid Cancer -- Evaluation -- Role of Molecular Testing in Thyroid Cancer", "content": "While CT and MRI scans are not routine modalities in evaluating thyroid nodules for malignancies, their use may be appropriate in assessing local spread in more advanced diseases or those with enlarged cervical nodes in association with a suspicious mass. [45] A CT scan should be advised for patients with thyroid mass with extension into the substernal region confirmed by ultrasound or plain radiographs.", "contents": "Thyroid Cancer -- Evaluation -- Role of Molecular Testing in Thyroid Cancer. While CT and MRI scans are not routine modalities in evaluating thyroid nodules for malignancies, their use may be appropriate in assessing local spread in more advanced diseases or those with enlarged cervical nodes in association with a suspicious mass. [45] A CT scan should be advised for patients with thyroid mass with extension into the substernal region confirmed by ultrasound or plain radiographs."}
{"id": "article-30139_27", "title": "Thyroid Cancer -- Treatment / Management -- Surgical Treatment", "content": "Surgical resection\u00a0remains the main treatment modality of\u00a0both PTC and FTC, followed by\u00a0radioiodine ablation (RAI ablation) when indicated and\u00a0suppression therapy with thyroid hormone. [34] [46] Systemic radiation and chemotherapy seldom play a significant role in treatment, although they may be used in advanced cases refractory to conventional methods. To minimize the risk of complications, specifically recurrent laryngeal nerve injury and hypoparathyroidism, surgery is recommended, performed by experienced, \"high-volume\" thyroid surgeons. [47]", "contents": "Thyroid Cancer -- Treatment / Management -- Surgical Treatment. Surgical resection\u00a0remains the main treatment modality of\u00a0both PTC and FTC, followed by\u00a0radioiodine ablation (RAI ablation) when indicated and\u00a0suppression therapy with thyroid hormone. [34] [46] Systemic radiation and chemotherapy seldom play a significant role in treatment, although they may be used in advanced cases refractory to conventional methods. To minimize the risk of complications, specifically recurrent laryngeal nerve injury and hypoparathyroidism, surgery is recommended, performed by experienced, \"high-volume\" thyroid surgeons. [47]"}
{"id": "article-30139_28", "title": "Thyroid Cancer -- Treatment / Management -- Surgical Treatment", "content": "Pre-operative neck ultrasound is\u00a0pivotal in deciding the appropriate surgical procedure.\u00a0Surgical\u00a0resection can\u00a0be hemithyroidectomy or total thyroidectomy, with or without lymph node dissection. The choice of surgery depends on tumor size, presence of lymph node metastasis, extra-thyroidal extension, age of the patient, and the presence or absence of co-morbid conditions. In patients with locally advanced disease, additional imaging of the neck is advised.", "contents": "Thyroid Cancer -- Treatment / Management -- Surgical Treatment. Pre-operative neck ultrasound is\u00a0pivotal in deciding the appropriate surgical procedure.\u00a0Surgical\u00a0resection can\u00a0be hemithyroidectomy or total thyroidectomy, with or without lymph node dissection. The choice of surgery depends on tumor size, presence of lymph node metastasis, extra-thyroidal extension, age of the patient, and the presence or absence of co-morbid conditions. In patients with locally advanced disease, additional imaging of the neck is advised."}
{"id": "article-30139_29", "title": "Thyroid Cancer -- Treatment / Management -- Surgical Treatment", "content": "A thyroid lobectomy is preferred for unilateral DTC < 1 cm, without any extra-thyroidal or lymph node invasion, unless there are clear indications for total thyroidectomy, such as childhood head and neck irradiation or a strong family history of thyroid cancer. Lately, there is also a trend for just active surveillance without immediate surgery, but more studies are needed to show the difference, if any, in the outcomes and prognosis. [48]", "contents": "Thyroid Cancer -- Treatment / Management -- Surgical Treatment. A thyroid lobectomy is preferred for unilateral DTC < 1 cm, without any extra-thyroidal or lymph node invasion, unless there are clear indications for total thyroidectomy, such as childhood head and neck irradiation or a strong family history of thyroid cancer. Lately, there is also a trend for just active surveillance without immediate surgery, but more studies are needed to show the difference, if any, in the outcomes and prognosis. [48]"}
{"id": "article-30139_30", "title": "Thyroid Cancer -- Treatment / Management -- Surgical Treatment", "content": "For tumor sizes\u00a0between 1\u00a0and 4 cm with no extrathyroidal or lymphatic invasion, the procedure of choice can either be a total thyroidectomy or lobectomy, depending on patient preferences and risk factors, as described above. This decision\u00a0should be made with the patient aware\u00a0that a completion thyroidectomy\u00a0may be necessary depending on pathology results.", "contents": "Thyroid Cancer -- Treatment / Management -- Surgical Treatment. For tumor sizes\u00a0between 1\u00a0and 4 cm with no extrathyroidal or lymphatic invasion, the procedure of choice can either be a total thyroidectomy or lobectomy, depending on patient preferences and risk factors, as described above. This decision\u00a0should be made with the patient aware\u00a0that a completion thyroidectomy\u00a0may be necessary depending on pathology results."}
{"id": "article-30139_31", "title": "Thyroid Cancer -- Treatment / Management -- Surgical Treatment", "content": "For tumors > 4 cm\u00a0or tumors\u00a0with extra-thyroidal or lymph node invasion, a total thyroidectomy is the preferred surgical procedure as there is a high risk of multifocal carcinoma in such cancers. It is also intended to facilitate RAI ablation and future surveillance with thyroglobulin as a tumor marker.", "contents": "Thyroid Cancer -- Treatment / Management -- Surgical Treatment. For tumors > 4 cm\u00a0or tumors\u00a0with extra-thyroidal or lymph node invasion, a total thyroidectomy is the preferred surgical procedure as there is a high risk of multifocal carcinoma in such cancers. It is also intended to facilitate RAI ablation and future surveillance with thyroglobulin as a tumor marker."}
{"id": "article-30139_32", "title": "Thyroid Cancer -- Treatment / Management -- Surgical Treatment", "content": "The decision for lymph node dissection should be made on a patient-by-patient basis, and there is still a lot of controversy about the proven survival benefit of prophylactic node dissection. Regardless, all patients with proven or suspected PTC should undergo a\u00a0thorough examination of both the central and lateral neck for possible nodal metastasis. The lateral neck compartments are not routinely entered in\u00a0thyroidectomy and should be assessed preoperatively with ultrasound and subsequent FNAB if there is a\u00a0concern for lymphatic spread.\u00a0If pathologic nodes are confirmed, an ipsilateral neck dissection should be carried out, with a formal clearance of defined lymph node compartments as opposed to isolated \"berry-picking\" of diseased nodes. The central neck\u00a0lymph nodes are difficult to assess preoperatively due to their location. A careful inspection and palpation of the central neck should be performed at the time of surgery, with subsequent compartmental neck dissection if abnormal nodes are\u00a0found.", "contents": "Thyroid Cancer -- Treatment / Management -- Surgical Treatment. The decision for lymph node dissection should be made on a patient-by-patient basis, and there is still a lot of controversy about the proven survival benefit of prophylactic node dissection. Regardless, all patients with proven or suspected PTC should undergo a\u00a0thorough examination of both the central and lateral neck for possible nodal metastasis. The lateral neck compartments are not routinely entered in\u00a0thyroidectomy and should be assessed preoperatively with ultrasound and subsequent FNAB if there is a\u00a0concern for lymphatic spread.\u00a0If pathologic nodes are confirmed, an ipsilateral neck dissection should be carried out, with a formal clearance of defined lymph node compartments as opposed to isolated \"berry-picking\" of diseased nodes. The central neck\u00a0lymph nodes are difficult to assess preoperatively due to their location. A careful inspection and palpation of the central neck should be performed at the time of surgery, with subsequent compartmental neck dissection if abnormal nodes are\u00a0found."}
{"id": "article-30139_33", "title": "Thyroid Cancer -- Treatment / Management -- Postsurgical Risk Stratification", "content": "Postsurgical risk stratification\u00a0must be performed to determine the need for additional treatment, especially with RAI ablation. The TNM\u00a0(Tumor,\u00a0Node,\u00a0Metastasis) risk stratification by the American Joint Commission on Cancer(AJCC)\u00a0predicts disease-specific mortality, while the American Thyroid Association (ATA) risk stratification system, which is widely used, helps predict the persistence or recurrence of residual cancer. [49]", "contents": "Thyroid Cancer -- Treatment / Management -- Postsurgical Risk Stratification. Postsurgical risk stratification\u00a0must be performed to determine the need for additional treatment, especially with RAI ablation. The TNM\u00a0(Tumor,\u00a0Node,\u00a0Metastasis) risk stratification by the American Joint Commission on Cancer(AJCC)\u00a0predicts disease-specific mortality, while the American Thyroid Association (ATA) risk stratification system, which is widely used, helps predict the persistence or recurrence of residual cancer. [49]"}
{"id": "article-30139_34", "title": "Thyroid Cancer -- Treatment / Management -- Postsurgical Risk Stratification", "content": "The ATA system classifies patients as low, intermediate, or high risk based on clinicopathologic findings, including but not limited to tumor size, histologic type, vascular or lymph node involvement, local invasion, distant metastasis, the extent of tumor resection, post-operative thyroglobulin levels, and post-operative radioiodine uptake outside of the thyroid gland. [34] [50] [34]", "contents": "Thyroid Cancer -- Treatment / Management -- Postsurgical Risk Stratification. The ATA system classifies patients as low, intermediate, or high risk based on clinicopathologic findings, including but not limited to tumor size, histologic type, vascular or lymph node involvement, local invasion, distant metastasis, the extent of tumor resection, post-operative thyroglobulin levels, and post-operative radioiodine uptake outside of the thyroid gland. [34] [50] [34]"}
{"id": "article-30139_35", "title": "Thyroid Cancer -- Treatment / Management -- Postsurgical Risk Stratification", "content": "The\u00a0 TNM-AJCC system accounts for factors such as the tumor size, the presence and extent of extra-thyroidal invasion, the number of nodal metastases, and whether there is the presence of distal metastasis. Age is a significant factor in predicting mortality in thyroid cancer patients, and its role is also significant in staging the disease. Patients under 55 years old at the time of diagnosis will receive a stage II diagnosis at the most. [51]", "contents": "Thyroid Cancer -- Treatment / Management -- Postsurgical Risk Stratification. The\u00a0 TNM-AJCC system accounts for factors such as the tumor size, the presence and extent of extra-thyroidal invasion, the number of nodal metastases, and whether there is the presence of distal metastasis. Age is a significant factor in predicting mortality in thyroid cancer patients, and its role is also significant in staging the disease. Patients under 55 years old at the time of diagnosis will receive a stage II diagnosis at the most. [51]"}
{"id": "article-30139_36", "title": "Thyroid Cancer -- Treatment / Management -- Radioiodine (RAI) Ablation Therapy", "content": "RAI therapy after thyroidectomy\u00a0is used for remnant ablation of normal residual thyroid tissue, as adjuvant therapy for\u00a0subclinical micrometastases, or as treatment of apparent local or distant metastasis. [52] High-risk and some selected intermediate-risk patients, per the ATA risk stratification system, will benefit from RAI ablation.\u00a0Patients who are candidates for RAI therapy\u00a0should maintain a low iodine diet for 1 to 2 weeks before the treatment to ensure iodine depletion of the cells; they should also be cautioned against large iodine administrations such as through iodinated contrast or amiodarone to improve the avidity of the thyroid follicular cells to iodine.\u00a0RAI ablation works best when thyroid hormone has been withdrawn, with a goal thyroid-stimulating hormone (TSH) of 30mIU/liter or higher. This level of TSH can be achieved either through the withdrawal of thyroid hormones or the administration of exogenous recombinant human TSH.", "contents": "Thyroid Cancer -- Treatment / Management -- Radioiodine (RAI) Ablation Therapy. RAI therapy after thyroidectomy\u00a0is used for remnant ablation of normal residual thyroid tissue, as adjuvant therapy for\u00a0subclinical micrometastases, or as treatment of apparent local or distant metastasis. [52] High-risk and some selected intermediate-risk patients, per the ATA risk stratification system, will benefit from RAI ablation.\u00a0Patients who are candidates for RAI therapy\u00a0should maintain a low iodine diet for 1 to 2 weeks before the treatment to ensure iodine depletion of the cells; they should also be cautioned against large iodine administrations such as through iodinated contrast or amiodarone to improve the avidity of the thyroid follicular cells to iodine.\u00a0RAI ablation works best when thyroid hormone has been withdrawn, with a goal thyroid-stimulating hormone (TSH) of 30mIU/liter or higher. This level of TSH can be achieved either through the withdrawal of thyroid hormones or the administration of exogenous recombinant human TSH."}
{"id": "article-30139_37", "title": "Thyroid Cancer -- Treatment / Management -- Thyroid Hormone Suppression Therapy", "content": "Thyroid hormone suppression therapy to suppress TSH and thereby potentially minimize its stimulation of thyroid cancer growth is\u00a0recommended in most patients after surgery. For\u00a0patients\u00a0with ATA high-risk, the goal TSH should be no more than 0.1m IU/liter, and for patients in the intermediate-risk category, the goal TSH should be between 0.1\u00a0and 0.5 mIU/liter. For the ATA\u00a0low-risk category, a goal TSH between 0.5\u00a0and 2.0 mIU/liter is acceptable. [53] [54] [53]", "contents": "Thyroid Cancer -- Treatment / Management -- Thyroid Hormone Suppression Therapy. Thyroid hormone suppression therapy to suppress TSH and thereby potentially minimize its stimulation of thyroid cancer growth is\u00a0recommended in most patients after surgery. For\u00a0patients\u00a0with ATA high-risk, the goal TSH should be no more than 0.1m IU/liter, and for patients in the intermediate-risk category, the goal TSH should be between 0.1\u00a0and 0.5 mIU/liter. For the ATA\u00a0low-risk category, a goal TSH between 0.5\u00a0and 2.0 mIU/liter is acceptable. [53] [54] [53]"}
{"id": "article-30139_38", "title": "Thyroid Cancer -- Treatment / Management -- Persistent or Recurrent Disease", "content": "For recurrent minimal iodine-avid disease, RAI ablation is the preferred therapy. For invasive neck disease, surgical resection is recommended. Percutaneous ethanol injection [55] has been tried for cervical lymph node metastasis. For small distant metastasis to bones or lungs, radiofrequency ablation has been used. Other treatment options are external beam radiation and systemic chemotherapy.", "contents": "Thyroid Cancer -- Treatment / Management -- Persistent or Recurrent Disease. For recurrent minimal iodine-avid disease, RAI ablation is the preferred therapy. For invasive neck disease, surgical resection is recommended. Percutaneous ethanol injection [55] has been tried for cervical lymph node metastasis. For small distant metastasis to bones or lungs, radiofrequency ablation has been used. Other treatment options are external beam radiation and systemic chemotherapy."}
{"id": "article-30139_39", "title": "Thyroid Cancer -- Treatment / Management -- Systemic Chemotherapy", "content": "Systemic chemotherapy is usually only considered in a group of carefully selected patients with a high metastatic disease burden or rapidly progressive metastatic disease despite the above treatment (Iodide-refractory). Because of the significant adverse effects associated with such therapy,\u00a0it should be considered only when the associated benefits exceed the risks. [34]", "contents": "Thyroid Cancer -- Treatment / Management -- Systemic Chemotherapy. Systemic chemotherapy is usually only considered in a group of carefully selected patients with a high metastatic disease burden or rapidly progressive metastatic disease despite the above treatment (Iodide-refractory). Because of the significant adverse effects associated with such therapy,\u00a0it should be considered only when the associated benefits exceed the risks. [34]"}
{"id": "article-30139_40", "title": "Thyroid Cancer -- Treatment / Management -- Systemic Chemotherapy", "content": "Systemic chemotherapy for DTC is preferably administered through a clinical trial. The common agents of choice are the kinase inhibitor class of drugs such as anti-angiogenic multi-targeted kinase inhibitors (aaMKI- lenvatinib, sorafenib), BRAF kinase inhibitors (vemurafenib, dabrafenib), MEK inhibitors (trametinib, cobimetinib), NTR kinase inhibitors (larotrectinib), and RET inhibitor (selpercatinib). [56] The choice of agent depends on the occurrence of specific gene mutations or signaling irregularities such as those described above. For patients with no identifiable mutations,\u00a0aaMKIs are\u00a0the recommended first-line therapy.", "contents": "Thyroid Cancer -- Treatment / Management -- Systemic Chemotherapy. Systemic chemotherapy for DTC is preferably administered through a clinical trial. The common agents of choice are the kinase inhibitor class of drugs such as anti-angiogenic multi-targeted kinase inhibitors (aaMKI- lenvatinib, sorafenib), BRAF kinase inhibitors (vemurafenib, dabrafenib), MEK inhibitors (trametinib, cobimetinib), NTR kinase inhibitors (larotrectinib), and RET inhibitor (selpercatinib). [56] The choice of agent depends on the occurrence of specific gene mutations or signaling irregularities such as those described above. For patients with no identifiable mutations,\u00a0aaMKIs are\u00a0the recommended first-line therapy."}
{"id": "article-30139_41", "title": "Thyroid Cancer -- Treatment / Management -- Dynamic Risk Stratification", "content": "After the initial postsurgical risk stratification and appropriate treatment as above, patients should be re-stratified\u00a0during each follow-up visit depending on their response to therapy into one of the following clinical outcomes:\u00a01. Excellent response, 2. Biochemical incomplete response, 3. Structural incomplete response, 4. Indeterminate response. [57] [58] [59]", "contents": "Thyroid Cancer -- Treatment / Management -- Dynamic Risk Stratification. After the initial postsurgical risk stratification and appropriate treatment as above, patients should be re-stratified\u00a0during each follow-up visit depending on their response to therapy into one of the following clinical outcomes:\u00a01. Excellent response, 2. Biochemical incomplete response, 3. Structural incomplete response, 4. Indeterminate response. [57] [58] [59]"}
{"id": "article-30139_42", "title": "Thyroid Cancer -- Treatment / Management -- Dynamic Risk Stratification", "content": "Monitoring in the first postsurgical year primarily involves a thyroid ultrasound scan every 6\u00a0to 12 months and TSH and thyroglobulin levels every 3\u00a0to 6 months, depending on risk. For higher-risk patients, additional imaging such as CT scan, MRI, FDG-PET, or whole-body radioiodine scanning is required. After one year, the frequency of monitoring depends on the dynamic risk stratification.", "contents": "Thyroid Cancer -- Treatment / Management -- Dynamic Risk Stratification. Monitoring in the first postsurgical year primarily involves a thyroid ultrasound scan every 6\u00a0to 12 months and TSH and thyroglobulin levels every 3\u00a0to 6 months, depending on risk. For higher-risk patients, additional imaging such as CT scan, MRI, FDG-PET, or whole-body radioiodine scanning is required. After one year, the frequency of monitoring depends on the dynamic risk stratification."}
{"id": "article-30139_43", "title": "Thyroid Cancer -- Treatment / Management -- Medullary Thyroid Cancer", "content": "Surgical therapy\u00a0that includes total thyroidectomy with\u00a0resection of local and regional metastases is the mainstay of treatment for MTC. In most patients with confirmed MTC and no evidence of pre-operative cervical lymph node metastasis on ultrasound, prophylactic\u00a0central lymph node dissection should be performed at the time of the total thyroidectomy. Patients with confirmed lateral zone nodal metastases should receive lateral compartment dissection, central neck dissection, and total thyroidectomy. Serum calcitonin, carcinoembryonic antigen, and biochemical testing for coexisting hyperparathyroidism and pheochromocytoma should be performed. Patients should be monitored long-term with serial calcitonin levels, neck ultrasound, and physical examination. Of note, as MTC is not of follicular origin, there is no role for radioiodine ablation or TSH suppression in\u00a0its management. [60] For refractory MTC, systemic chemotherapy with kinase inhibitors has been shown to be beneficial. RET-specific kinase inhibitors are preferred in patients with RET mutation, while in patients negative for RET mutation, aaMKIs are the preferred drugs.", "contents": "Thyroid Cancer -- Treatment / Management -- Medullary Thyroid Cancer. Surgical therapy\u00a0that includes total thyroidectomy with\u00a0resection of local and regional metastases is the mainstay of treatment for MTC. In most patients with confirmed MTC and no evidence of pre-operative cervical lymph node metastasis on ultrasound, prophylactic\u00a0central lymph node dissection should be performed at the time of the total thyroidectomy. Patients with confirmed lateral zone nodal metastases should receive lateral compartment dissection, central neck dissection, and total thyroidectomy. Serum calcitonin, carcinoembryonic antigen, and biochemical testing for coexisting hyperparathyroidism and pheochromocytoma should be performed. Patients should be monitored long-term with serial calcitonin levels, neck ultrasound, and physical examination. Of note, as MTC is not of follicular origin, there is no role for radioiodine ablation or TSH suppression in\u00a0its management. [60] For refractory MTC, systemic chemotherapy with kinase inhibitors has been shown to be beneficial. RET-specific kinase inhibitors are preferred in patients with RET mutation, while in patients negative for RET mutation, aaMKIs are the preferred drugs."}
{"id": "article-30139_44", "title": "Thyroid Cancer -- Treatment / Management -- Anaplastic Thyroid Cancer", "content": "In patients diagnosed with anaplastic thyroid cancer, BRAF V600E mutation testing and staging are performed. Resectable disease is surgically removed, followed by specific BRAF kinase inhibitors in patients with BRAF V600E mutations. Other patients received targeted radiation treatment and cytotoxic chemotherapy after surgery. However, distant metastases are common in patients even at initial diagnosis due to their rapidly progressive course, and local invasion into the trachea or vasculature\u00a0may occur, making it unresectable. Mortality\u00a0is near 100% for these cancers, and a conservative surgical approach for palliation can be considered in\u00a0such high-risk patients.", "contents": "Thyroid Cancer -- Treatment / Management -- Anaplastic Thyroid Cancer. In patients diagnosed with anaplastic thyroid cancer, BRAF V600E mutation testing and staging are performed. Resectable disease is surgically removed, followed by specific BRAF kinase inhibitors in patients with BRAF V600E mutations. Other patients received targeted radiation treatment and cytotoxic chemotherapy after surgery. However, distant metastases are common in patients even at initial diagnosis due to their rapidly progressive course, and local invasion into the trachea or vasculature\u00a0may occur, making it unresectable. Mortality\u00a0is near 100% for these cancers, and a conservative surgical approach for palliation can be considered in\u00a0such high-risk patients."}
{"id": "article-30139_45", "title": "Thyroid Cancer -- Differential Diagnosis", "content": "Benign thyroid nodule Toxic nodular goiter Primary thyroid lymphoma Cervical lymphadenopathy", "contents": "Thyroid Cancer -- Differential Diagnosis. Benign thyroid nodule Toxic nodular goiter Primary thyroid lymphoma Cervical lymphadenopathy"}
{"id": "article-30139_46", "title": "Thyroid Cancer -- Prognosis", "content": "The prognosis of thyroid cancer\u00a0varies greatly, depending on its type, tumor size, the extent of metastasis, patient's age, and amenability to resection. The prognosis is generally good, with up to 95% 5-year survival rate for patients of all ages and races. Poor prognostic factors include large tumor size, the presence of extra-thyroidal extensions or metastases, older age, or unfavorable tumor types such as undifferentiated cancer. [61]", "contents": "Thyroid Cancer -- Prognosis. The prognosis of thyroid cancer\u00a0varies greatly, depending on its type, tumor size, the extent of metastasis, patient's age, and amenability to resection. The prognosis is generally good, with up to 95% 5-year survival rate for patients of all ages and races. Poor prognostic factors include large tumor size, the presence of extra-thyroidal extensions or metastases, older age, or unfavorable tumor types such as undifferentiated cancer. [61]"}
{"id": "article-30139_47", "title": "Thyroid Cancer -- Complications", "content": "Untreated\u00a0thyroid cancer can be locally invasive into the airway, esophagus, or other nearby neurovascular structures. Distant metastasis most commonly involves the lung, bone, and other soft tissue structures.", "contents": "Thyroid Cancer -- Complications. Untreated\u00a0thyroid cancer can be locally invasive into the airway, esophagus, or other nearby neurovascular structures. Distant metastasis most commonly involves the lung, bone, and other soft tissue structures."}
{"id": "article-30139_48", "title": "Thyroid Cancer -- Complications", "content": "Both thyroid lobectomy and total thyroidectomy carry the potential for neurovascular injuries, with the most common involving the recurrent laryngeal nerve, leading to hoarseness of voice and potentially respiratory failure with bilateral injuries. Treatment of thyroid cancer during pregnancy, mostly with thyroidectomy, did not show any significant increase in the complications of pregnancy. [62]", "contents": "Thyroid Cancer -- Complications. Both thyroid lobectomy and total thyroidectomy carry the potential for neurovascular injuries, with the most common involving the recurrent laryngeal nerve, leading to hoarseness of voice and potentially respiratory failure with bilateral injuries. Treatment of thyroid cancer during pregnancy, mostly with thyroidectomy, did not show any significant increase in the complications of pregnancy. [62]"}
{"id": "article-30139_49", "title": "Thyroid Cancer -- Consultations", "content": "Thyroid surgeon Endocrinologist Radiologist Pathologist", "contents": "Thyroid Cancer -- Consultations. Thyroid surgeon Endocrinologist Radiologist Pathologist"}
{"id": "article-30139_50", "title": "Thyroid Cancer -- Deterrence and Patient Education", "content": "As previously discussed, patients with risk factors, such as prior irradiation to the head and neck area and a family history of thyroid cancer, should be screened for thyroid cancer, especially when such a patient presents with thyroid nodules with or without pressure symptoms.", "contents": "Thyroid Cancer -- Deterrence and Patient Education. As previously discussed, patients with risk factors, such as prior irradiation to the head and neck area and a family history of thyroid cancer, should be screened for thyroid cancer, especially when such a patient presents with thyroid nodules with or without pressure symptoms."}
{"id": "article-30139_51", "title": "Thyroid Cancer -- Enhancing Healthcare Team Outcomes", "content": "Thyroid cancer, as discussed, can have highly varied manifestations, from a clinically indolent low-risk disease that can be managed with only active surveillance to a highly aggressive metastatic disease that needs extensive surgical resection with or without systemic chemotherapy.", "contents": "Thyroid Cancer -- Enhancing Healthcare Team Outcomes. Thyroid cancer, as discussed, can have highly varied manifestations, from a clinically indolent low-risk disease that can be managed with only active surveillance to a highly aggressive metastatic disease that needs extensive surgical resection with or without systemic chemotherapy."}
{"id": "article-30139_52", "title": "Thyroid Cancer -- Enhancing Healthcare Team Outcomes", "content": "Hence, managing a patient with thyroid cancer is a highly individualized process taking into account\u00a0the patient's risk of recurrence and preferences (after being educated about the different treatment strategies and risks vs. benefits of each). A close collaboration between all interprofessional team members, including but not limited to the thyroid surgeon, the endocrinologist, the pathologist, the radiologist, and possibly the oncologist, plays a vital role in providing the most appropriate treatment for the patient while avoiding overtreatment at the same time. Nursing staff should ensure the patient is involved and comfortable every step of the way, from pre-operative planning to treatment and postoperative monitoring. When pursuing chemotherapy, a specialized oncology pharmacist is also a valuable addition to the interprofessional team. Interprofessional teamwork relies on open communication channels between all team members, and the maintaining of meticulous records so that all professionals involved in the case have access to the same updated patient information and can reach out to other team members if they see anything that requires their attention. This type of interprofessional care coordination combined with open information sharing will yield the best patient outcomes. [Level 5]", "contents": "Thyroid Cancer -- Enhancing Healthcare Team Outcomes. Hence, managing a patient with thyroid cancer is a highly individualized process taking into account\u00a0the patient's risk of recurrence and preferences (after being educated about the different treatment strategies and risks vs. benefits of each). A close collaboration between all interprofessional team members, including but not limited to the thyroid surgeon, the endocrinologist, the pathologist, the radiologist, and possibly the oncologist, plays a vital role in providing the most appropriate treatment for the patient while avoiding overtreatment at the same time. Nursing staff should ensure the patient is involved and comfortable every step of the way, from pre-operative planning to treatment and postoperative monitoring. When pursuing chemotherapy, a specialized oncology pharmacist is also a valuable addition to the interprofessional team. Interprofessional teamwork relies on open communication channels between all team members, and the maintaining of meticulous records so that all professionals involved in the case have access to the same updated patient information and can reach out to other team members if they see anything that requires their attention. This type of interprofessional care coordination combined with open information sharing will yield the best patient outcomes. [Level 5]"}
{"id": "article-30139_53", "title": "Thyroid Cancer -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Thyroid Cancer -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}